Treatment of schizophrenia; treatment of moderate to severe manic episodes in bipolar disorders; treatment of severe aggression in patients with dementia of the Alzheimer’s type from moderate to severe degree when there is a threat of harming oneself or others and when there is no response to non-pharmacological methods of treatment; symptomatic treatment of severe aggression in behavioral disorders in children over 5 years of age and adolescents with below-average mental development or mental retardation diagnosed according to DSM-IV criteria, in which the severity of aggressive or other destructive behavior requires pharmacological treatment.
Rispolept (risperidone) oral solution 1 mg/ml. 30 ml. vial
active substance: risperidone;
1 ml of solution contains 1 mg of risperidone;
excipients: tartaric acid, benzoic acid (E 210), sodium hydroxide, purified water.
Main physicochemical properties: transparent, colorless solution.
ATX code N05A X08.
Risperidone is a selective monoaminergic antagonist with unique properties. It shows high affinity for serotonergic 5-HT2 and dopaminergic D2 receptors. Risperidone also binds to α1-adrenergic receptors and with lower affinity to H1-histaminergic and α2-adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although risperidone is a potent D2-antagonist, which has been attributed to its efficacy on the productive symptoms of schizophrenia, it does not cause a significant inhibition of motor activity and induces catalepsy to a lesser extent compared to classical antipsychotics. Balanced central antagonism with respect to serotonin and dopamine reduces susceptibility to extrapyramidal side effects and extends the therapeutic effect of the drug to include negative and affective symptoms of schizophrenia.
Rispolept is used to treat patients suffering from various forms of schizophrenia, as well as patients with the first episode of psychosis and other psychotic disorders, accompanied by the development of severe negative or productive symptoms, such as hostility, suspicion, poor speech, social and emotional withdrawal, impaired thinking, hallucinations.
The drug can be used in the treatment of patients with schizoaffective disorders and a form of schizophrenia, accompanied by the development of affective symptoms: anxiety, fear, depression.
Rispolept is used to prevent the onset of acute psychotic conditions in patients suffering from chronic schizophrenia. In addition, the drug can be used for the prophylaxis and therapy of behavioral disorders in patients with dementia, accompanied by the development of increased aggression, behavior disorders and psychotic symptoms in the patient. Also Rispolept can be used in the complex treatment of bipolar disorders, in which manic episodes are observed.
Rispolept is not used during lactation, for the treatment of children under 15 years of age and hypersensitivity to risperidone.
The drug is prescribed with caution to those who suffer from cardiovascular diseases, impaired cardiac muscle conduction, cerebrovascular accident, Parkinson’s disease and suffered myocardial infarction. Also, it is recommended to refrain from the appointment of Rispolepta if the patient has a history of convulsive syndrome, renal or hepatic failure, drug dependence, intestinal obstruction, brain neoplasms and pregnancy.
Application for pregnancy and lactation
Rispolept is not used to treat pregnant women. If treatment with the drug is necessary for a patient at the lactation stage, it is recommended to refuse breastfeeding.
Method of administration and dosage
When used in Rispolepta therapy, the dose is selected individually. The starting daily dose on the first day in the treatment of adults can be from 0.25 to 2 mg, on the 2nd day – 4 mg. In the future, the dose of the drug either remains unchanged or is adjusted depending on the patient’s condition and can range from 0.5 to 6 mg per day. Sometimes it is advisable to increase the dose more slowly, as well as to prescribe a lower maintenance and initial dose. The maximum daily dose of Rispolepta is 16 mg.
When taking Rispolepta in high doses, the patient may experience drowsiness, tachycardia, hypotension and the development of extrapyramidal symptoms. The patient is prescribed gastric lavage, the intake of enerosorbents and symptomatic treatment.
When treating with Rispolept, a patient may develop undesirable symptoms from the central nervous system, gastrointestinal tract and cardiovascular system. Also, in some patients with prolonged use of the drug, allergic reactions occur.